Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samia Joseph Khoury, M.D.

Co-Author

This page shows the publications co-authored by Samia Khoury and David Hafler.
Connection Strength

0.982
  1. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 Sep; 67(9):1055-61.
    View in: PubMed
    Score: 0.118
  2. TGF-beta induces IL-9 production from human Th17 cells. J Immunol. 2010 Jul 01; 185(1):46-54.
    View in: PubMed
    Score: 0.116
  3. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16; 71(12):917-24.
    View in: PubMed
    Score: 0.103
  4. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol. 2003 Mar; 136(1-2):140-8.
    View in: PubMed
    Score: 0.070
  5. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci. 1997 Dec 19; 835:120-31.
    View in: PubMed
    Score: 0.049
  6. Oral administration of myelin induces antigen-specific TGF-beta 1-secreting T cells in multiple sclerosis patients. Ann N Y Acad Sci. 1997 Apr 05; 815:412-22.
    View in: PubMed
    Score: 0.047
  7. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996 Jul 01; 98(1):70-7.
    View in: PubMed
    Score: 0.044
  8. Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. Ann N Y Acad Sci. 1996 Feb 13; 778:251-7.
    View in: PubMed
    Score: 0.043
  9. Therapy for multiple sclerosis. Neurol Clin. 1995 Feb; 13(1):173-96.
    View in: PubMed
    Score: 0.040
  10. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994; 12:809-37.
    View in: PubMed
    Score: 0.037
  11. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.037
  12. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26; 259(5099):1321-4.
    View in: PubMed
    Score: 0.035
  13. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
    View in: PubMed
    Score: 0.034
  14. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.030
  15. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.030
  16. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009 Sep 15; 183(6):4067-76.
    View in: PubMed
    Score: 0.028
  17. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain. 2008 Jul; 131(Pt 7):1701-11.
    View in: PubMed
    Score: 0.025
  18. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol. 2006 Sep 15; 177(6):4196-202.
    View in: PubMed
    Score: 0.022
  19. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999 Dec; 5(6):403-9.
    View in: PubMed
    Score: 0.014
  20. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol. 1998 Jul; 88(1):28-34.
    View in: PubMed
    Score: 0.013
  21. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol. 1997 Sep; 42(3):313-8.
    View in: PubMed
    Score: 0.012
  22. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 Jan 21; 94(2):599-603.
    View in: PubMed
    Score: 0.012
  23. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci. 1996 Feb 13; 778:243-50.
    View in: PubMed
    Score: 0.011
  24. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest. 1995 Jun; 95(6):2711-9.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.